Related Experiment Video

Updated: Mar 20, 2026

Author Spotlight: Innovating Thiol Quantification and Biomarker Detection for Oxidative Stress Research
03:35

Author Spotlight: Innovating Thiol Quantification and Biomarker Detection for Oxidative Stress Research

Published on: June 28, 2024

2.2K

Case control feasibility study assessing the association between severity of coronary artery disease with Glutathione

Dinushka Wickremasinghe1, Hemantha Peiris1, Lal Gotabhaya Chandrasena1

  • 1Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

BMC Cardiovascular Disorders
|May 28, 2016
PubMed

Insights

Glutathione peroxidase-1 (GPX-1) activity and Pro198Leu polymorphism are linked to coronary artery disease (CAD) in South Asians. Lower GPX-1 activity and the CT genotype increase CAD risk and susceptibility.

Area of Science:

  • Cardiovascular Genetics
  • Biomarker Discovery
  • Molecular Cardiology

Background:

  • Glutathione peroxidase-1 (GPX-1) activity is a potential marker for cardiovascular disease.
  • GPX-1 polymorphism's role in coronary artery disease (CAD) lacks data for South Asians.
  • This study investigates GPX-1 activity and polymorphism in South Asian CAD patients.

Purpose of the Study:

  • To assess GPX-1 activity and Pro198Leu polymorphism in South Asian patients with coronary artery disease (CAD).
  • To determine the association between GPX-1 genetic variations, enzyme activity, and CAD severity.
  • To evaluate GPX-1 as a potential biomarker for CAD risk in this population.

Main Methods:

  • A case-control study involving 85 CAD patients and 85 healthy controls (age/sex-matched).
  • Analysis of erythrocyte GPX-1 activity and Pro198Leu (CT) polymorphism.
  • CAD severity assessed using coronary angiography scoring.

Main Results:

  • A GPX-1 activity cutoff of 23.9 U/gHb demonstrated high sensitivity for ruling out major vessel disease.
  • The Pro198Leu (CT) polymorphism was significantly more prevalent in CAD patients (25.3%) than controls (10.7%).
  • Carriers of the CT genotype had a 2.84-fold increased risk of CAD.

Conclusions:

  • Individuals with Pro198Leu (CT) polymorphism exhibit lower erythrocyte GPX-1 activity.
  • This polymorphism is associated with increased susceptibility to coronary artery disease (CAD).
  • GPX-1 activity and Pro198Leu polymorphism are relevant factors in South Asian CAD.
Abstract

Keywords:
Coronary artery diseaseExtent scoreGPX-1 Pro198Leu polymorphismGlutathione PeroxidaseStenosis scoreVessel score

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Induction and Analysis of Oxidative Stress in Sleeping Beauty Transposon-Transfected Human Retinal Pigment Epithelial Cells10:00

Induction and Analysis of Oxidative Stress in Sleeping Beauty Transposon-Transfected Human Retinal Pigment Epithelial Cells

Published on: December 11, 2020

3.1K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
102
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
104
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
108
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K